Journal
INTERNATIONAL IMMUNOLOGY
Volume 13, Issue 5, Pages 633-641Publisher
OXFORD UNIV PRESS
DOI: 10.1093/intimm/13.5.633
Keywords
antigen presentation; CD16; Fc receptor; papillomavirus; vaccine; virus-like particles
Categories
Funding
- NCI NIH HHS [R01 CA74399, R01 CA74397, P01 CA74182] Funding Source: Medline
Ask authors/readers for more resources
Human papillomavirus virus-like particles (HPV VLP) and chimeric VLP are immunogens that are able to elicit potent anti-viral/tumor a and T cell responses. To investigate the immunogenicity of VLP, we determined which cells of the immune system are able to bind HPV-16 VLP, VLP were found to bind very well to human and mouse immune cells that expressed markers of antigen-presenting cells (APC) such as MHC class II, CD80 and CD86, including dendritic cells, macrophages and B cells, mAb blocking studies identified Fc gamma RIII (CD16) as one of the molecules to which the VLP can bind both on immune cells and foreskin epithelium. However, transfection of a CD16(-) hell line with CD16 did not confer binding of VLP. Splenocytes from Fc gamma RIII knockout mice Showed a 33% decrease in VLP binding overall and specifically to subsets of APC, These combined data support a role for CD16 as an accessory molecule in an HPV VLP-receptor complex, possibly contributing to the immunogenicity of HPV VLP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available